To The Moon

$BioNTech SE(BNTX)$ is expected to report their Q4 2024 quarterly earnings result on 10 March 2025. (to be confirmed).

Based on the analysts forecasts, the consensus estimate for revenue is expected at $1.15B, while the consensus EPS forecast for the quarter is $0.44. The reported EPS for the same quarter last year was $2.06.

BioNTech SE (BNTX) Last Positive Earnings Call Saw A Decline Of 0.58% In Share Price Since

BNTX last positive earnings call did not help its share price instead we saw a modest decline of 0.58% since.

The earnings call reflected a positive sentiment overall, driven by significant revenue growth, advancements in COVID-19 vaccines, and progress within the oncology pipeline. However, there were concerns regarding increased operating costs and contractual disputes. The financial guidance being at the lower end of the range was a noted challenge.

BioNTech SE (BNTX) Guidance On R&D Expense Control

In the third quarter of 2024, BioNTech reported revenues of approximately EUR 1.245 billion, a significant increase from the EUR 895 million achieved in the same period last year, largely due to the early approvals of their variant-adapted COVID-19 vaccines. The company's cost of sales amounted to EUR 179 million, while R&D expenses rose to EUR 550 million, reflecting progress in clinical trials for oncology pipeline candidates. SG&A expenses decreased to EUR 151 million, and other operating results were negatively impacted by EUR 355 million due to accruals for contractual disputes. BioNTech reported a net income of EUR 198 million, with diluted earnings per share of EUR 0.81, and maintained a robust cash position of EUR 17.8 billion.

The company adjusted its full-year revenue guidance to the lower end of its previous range, citing risks of write-downs and other charges, and decreased its SG&A and capital expenditures guidance by EUR 100 million each, while maintaining its R&D expense guidance.

Key Factors Influencing Q4 2024 Earnings

Analyzing BioNTech SE’s (BNTX) hypothetical Q4 2024 earnings requires balancing its declining COVID-19 vaccine revenue with progress in its oncology and infectious disease pipelines.

Here is a structured assessment of the key factors that may influence BNTX Q4 2024 earnings.

COVID-19 Vaccine Revenue

BioNTech reported total revenues of approximately EUR 1.245 billion for Q3 2024, compared to EUR 895 million for the same period in 2023, marking a significant increase attributed to early approvals of variant-adapted COVID-19 vaccines.

Successfully launched updated COVID-19 vaccines targeting latest variants, with distribution underway globally. Early strain recommendations and approvals enabled timely delivery for vaccination campaigns.

Declining Demand: As the pandemic transitions to endemic status, COVID-19 vaccine sales (historically >90% of revenue) will likely continue to shrink. Q4 2024 sales depend on:

Seasonal boosters (e.g., updated XBB.1.5 or future variant-targeted vaccines).

Transition from government contracts to commercial pricing (higher margins but lower volume).

Inventory Write-Downs: Excess doses or canceled orders could pressure margins.

Pipeline Progress

Oncology Programs: BioNTech’s mRNA cancer vaccines (e.g., BNT116 in NSCLC, partnered with Roche) and CAR-T/Cell therapies are critical for diversification. Clinical trial updates (e.g., Phase 2/3 data) in Q4 2024 could drive sentiment.

Advancements in bispecific immunomodulator BNT327 and mRNA cancer vaccine portfolio, including successful trials in triple-negative breast cancer and small cell lung cancer.

Infectious Diseases: Flu, malaria, or shingles vaccines (partnered with Pfizer, Gates Foundation) may see progress, but revenue impact will lag until approval (likely post-2025).

Cost Management

Reduced COVID revenue could widen losses if R&D spending (e.g., $2.2B in 2023) remains elevated. Margins will depend on balancing pipeline investment with cost discipline.

Partnerships and Collaborations:

Pfizer collaboration terms (e.g., profit-sharing adjustments for non-COVID products) and new deals (e.g., oncology alliances) could provide upfront payments or milestone revenue.

Showcased in-house AI company, InstaDeep, highlighting BioNTech's commitment to state-of-the-art AI in medical research and development.

Regulatory Catalysts:

Potential approvals for cancer vaccines or updates to COVID boosters (e.g., combination flu/COVID shots).

BioNTech accrued around EUR 600 million year-to-date for provisions related to contractual disputes with licensees and collaborators.

Financial Metrics to Watch

BioNTech expects full-year 2024 revenues to be at the low end of the guidance range due to low demand and pricing in low and middle-income countries, with anticipated write-downs impacting revenues.

Revenue: Consensus will focus on:

COVID vaccine sales (likely <1BinQ42024vs.1BinQ42024vs.4.3B in Q4 2022).

Non-COVID revenue (e.g., milestones, partnerships).

EPS: Negative earnings possible if COVID revenue decline outpaces cost cuts. Cost of sales increased to approximately EUR 179 million in Q3 2024 from EUR 162 million in the prior year. R&D expenses also rose to approximately EUR 550 million.

Cash Reserves: BioNTech’s ~€17B cash (2023) funds R&D but could dwindle if losses persist. BioNTech's cash and cash equivalents plus security investments reached approximately EUR 17.8 billion as of September 30, 2024, supporting continued investment in R&D.

BioNTech SE (BNTX) Price Target

Based on 11 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $144.02 with a high forecast of $170.00 and a low forecast of $120.00. The average price target represents a 29.95% change from the last price of $110.83.

If we were to see how BNTX share price would move before and after earnings, I would look at the bull and bear case factors.

Bull Case:

• Strong COVID Booster Uptake: Higher-than-expected commercial sales due to variant-driven demand.

• Pipeline Wins: Positive Phase 3 oncology data or accelerated regulatory pathways for cancer vaccines.

• New Partnerships: Licensing deals or upfront payments for infectious disease programs.

• Stock Reaction: Short-term rally on pipeline optimism despite weak COVID sales.

Bear Case:

• COVID Revenue Collapse: Faster-than-expected decline in vaccine sales (e.g., <$500M in Q4).

• Pipeline Delays: Setbacks in oncology trials or lack of near-term catalysts.

• R&D Burn: Mounting losses without clear commercialization timelines.

• Stock Reaction: Sell-off on weak guidance and concerns about cash runway.

From here, we can see that BNTX actually have these risks to consider which might impact its share price movement.

1. Over-Reliance on COVID Revenue: Slow pivot to oncology/infectious diseases.

2. Clinical Trial Failures: High-risk nature of cancer vaccine development.

3. Competition: Rival mRNA platforms (e.g., Moderna, CureVac) and traditional oncology therapies.

4. Macro Factors: Reduced healthcare spending in a recession.

Technical Analysis - Exponential Moving Average (EMA)

As seen above, BNTX is in a phase where it is transiting from pandemic windfalls to sustainable growth. So from how BNXT have been trading recently, we can see that it is in a sideway trend.

Investors are tolerating this short-term volatility as there is a need for patience for this stock to show oncology data validating its pipeline, but if that failed, we might see further downside.

RSI is showing weakness as there is an indication of bearish momentum seen, so we need to investors coming back to buy into this stock, and a good guidance and future might be able to help BNTX.

Summary

BioNTech’s Q4 2024 earnings will reflect:

1. COVID Cliff: The pace of revenue decline and margin impact from commercial pricing.

2. Pipeline Transition: Progress in oncology/infectious disease programs as the primary long-term value driver.

3. Cash Runway: Sustainability of R&D spend without near-term revenue.

Key Catalysts to Watch:

• Clinical trial updates for BNT116 (NSCLC) or BNT211 (CAR-T).

• Regulatory decisions on next-gen COVID boosters.

• Partnerships to monetize pipeline assets.

While BioNTech’s mRNA platform holds promise, Q4 2024 will likely highlight the challenges of transitioning from pandemic windfalls to sustainable growth.

As investor, we might need to tolerate short-term losses if oncology data validates its pipeline, but patience will be tested if milestones slip. Long-term success hinges on delivering a non-COVID blockbuster by 2025–2026.

Appreciate if you could share your thoughts in the comment section whether you think BNTX would be able to maintain its R&D expense as it transit from pandemic windfalls to sustainable growth.

@TigerStars @Daily_Discussion @Tiger_Earnings @TigerWire appreciate if you could feature this article so that fellow tiger would benefit from my investing and trading thoughts.

Disclaimer: The analysis and result presented does not recommend or suggest any investing in the said stock. This is purely for Analysis.